Company Overview - LENZ Therapeutics, Inc. currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [3] Price Performance - Over the past week, LENZ shares have increased by 3.37%, while the Zacks Medical - Biomedical and Genetics industry has decreased by 0.75% [5] - In the last month, LENZ's price has risen by 41.93%, significantly outperforming the industry's 2.78% [5] - Over the past quarter, LENZ shares have surged by 54.15%, and they have increased by 114.17% over the last year, compared to the S&P 500's gains of 13.08% and 38.58%, respectively [6] Trading Volume - LENZ's average 20-day trading volume is 177,779 shares, which serves as a baseline for price-to-volume analysis [7] Earnings Outlook - In the past two months, 4 earnings estimates for LENZ have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from -2.09 [9] - For the next fiscal year, 5 estimates have moved upwards with no downward revisions during the same period [9]
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know